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Abstract 
Mesothelioma is an aggressive cancer of pleural and peritoneal cells that is difficult to diagnose and 
monitor. Numerous studies have attempted to identify a blood or pleural fluid based biomarker that 
could be used in the diagnostic pathway. More recently there has been interest in the ability of 
serum/plasma biomarkers to monitor mesothelioma given development of newer treatments and 
limitations of radiological assessment. The majority of research has focused on soluble mesothelin 
(SM), a soluble glycoprotein expressed by mesothelial cells. Although SM lacks the sensitivity to be 
used as a stand alone diagnostic marker, when measured serially rising levels indicate disease 
progression and poor survival. High levels of other soluble glycoproteins, such as osteopontin, 
fibulin-3 and VEGF are independently associated with poor prognosis at baseline, although further 
research is required to ascertain any role outside of clinical trials. More recent literature has focused 
on the development of novel biomarkers from discovery cohorts. Although many DNA and mRNA 
biomarkers show promise in the diagnosis or screening of mesothelioma, none have been 
prospectively evaluated for use in clinical practice. In this review article we highlight the potential 
utility of biomarkers and evaluate the existing literature.  
Background 
Malignant mesothelioma is an aggressive and invariably fatal cancer of pleural and peritoneal cells 
(ratio 4:1), and less commonly the pericardium and tunica vaginalis. 1 The incidence of mesothelioma 
is increasing worldwide to the extent that it is now more common than cancers of the bladder and 
bone. Mesothelioma is almost exclusively caused by exposure to asbestos, a link that was first 
published by Wagner, a pathologist in South Africa, in 1960.2 He noticed that the incidence of pleural 
mesothelioma, a previously rare cancer, was increasing in areas of the Cape asbestos field which 
mined Cape Blue (crocidolite asbestos). The direct causal link between asbestos use in industry and 
mesothelioma allows for the future incidence of the disease to be predicted to some degree of 
accuracy. Given a mean latency of around 40 years from peak exposure 3 it is estimated that the 
incidence of mesothelioma in Europe will rise until  between 2015 and 2020 (add number of cases 
per year at peak). 4 Given ongoing unregulated use of asbestos in countries such as China, India and 
Russia, mesothelioma will continue to occur despite unequivocal evidence of its harms. The other 
rarer causes of mesothelioma are iatrogenic chest wall irradiation (e.g. in treatment of breast cancer 
or lymphoma) and exposure to erionite (a mineral found in Turkey). 5-8 
 
There are several different mechanisms by which asbestos is purported to cause mesothelioma.  The 
most widely accepted being that long thin asbestos fibres (over 5um in length) are inhaled into the 
lung, penetrating the lung epithelium and entering the pleural space. Then a continuous cycle of 
pleural irritation, damage and repair eventually results in the mutations giving rise to mesothelioma. 
The oxygen free radical hypothesis suggests that when asbestos fibres are phagocytosed there is 
release of oxygen free radicals that cause DNA damage and mutations.9 The finding that asbestos 
fibres penetrate mesothelial cells and interfere with mitosis, as well as inducing phosphorylation and 
production of various pro-oncogenic protein kinases (mitogen-activated protein and extracellular 
signal-regulated kinases 1 and 2), is another compelling argument of pathogenesis. Finally, the same 
cells release inflammatory tumour growth factor-β, platelet-derived growth factor and vascular 
endothelial growth factor (VEGF) which can be utilised by the malignant cells for proliferation and 
angiogenesis.4 It is likely that a combination of the above as well as various host-specific factors give 
rise to this malignancy.  
 
There are 4 main histological subtypes of mesothelioma (epithelioid, sarcomatoid, biphasic or mixed, 
and desmoplastic) which have different microscopic appearances and implications for the patient. 
Epithelioid is the most common variant (accounting for around 70% of cases in most series) and has 
the most favourable prognosis, with a median survival of 13.1 months.10, 11 The sarcomatoid variant 
is associated with the poorest prognosis, with a median survival of just 4 months. The histological 
subtype often has implications on treatments offered by oncologists or surgeons as more aggressive 
subtypes are felt to be not amenable to therapy. 
 
Clinical Presentation 
The majority of patients with malignant pleural mesothelioma will present with shortness of breath, 
cough or chest pain. Patients less commonly present from systemic symptoms of weight loss, night 
sweats and fatigue, and if they do this is a poor prognostic sign as the disease is likely more 
advanced.12  An abnormal chest radiograph may be the presenting complaint if some cases when 
performed routinely before an operation or for other medical reasons in patients without 
respiratory symptoms. A chest radiograph demonstrates a pleural effusion (fluid collection between 
the lung and chest wall) in 90% of cases, however this radiological sign is common in many malignant 
and non-malignant respiratory conditions.13 In patients who present with an abnormal chest 
radiograph, and known past asbestos exposure, malignant pleural mesothelioma should be high on 
the differential diagnosis. Even if the patient denies previous exposure to asbestos the diagnosis of 
mesothelioma should not be excluded given the risk of ‘second-hand’ or non-industrial exposures. 
Although symptoms from local spread can occur (including superior vena cava obstruction, rib 
destruction and laryngeal nerve palsy), clinical manifestations from metastatic spread are 
uncommon, due to the aggressive nature of the primary disease. 1 At post mortem most common 
areas of spread include the thoracic lymph nodes and bone. However, tract metastases in areas 
where the chest wall has been operated on either for diagnostic or therapeutic purposes are more 
common. These metastases can be disfiguring and/or painful and research is ongoing into the role of 
prophylactic radiotherapy following pleural procedures. 14, 15 
Peritoneal mesothelioma presents very differently to pleural disease, commonly with diffuse 
abdominal pain, abdominal swelling from disease bulk or ascites (fluid accumulation in the 
abdominal cavity), bowel obstruction, appetite loss or nausea. 
 
Imaging for mesothelioma 
As mentioned above, at initial presentation the majority of patients will have the fairly non-specific 
sign of a unilateral pleural effusion on chest radiograph (Figure 1A). A minority will have pleural 
thickening and fewer still will have evidence of advanced pleural disease with a widespread pleural 
rind (Figure 1C). In most cases an unexplained unilateral pleural effusion on chest radiograph will 
lead to a computerised tomography (CT) scan of the chest, abdomen and pelvis with the intention of 
identifying or excluding malignancy. Unfortunately, diagnosing mesothelioma on CT scan alone is 
difficult at early stage of disease given the likely presence of pleural fluid asbestos related plaques or 
folded lung which can obscure the radiologist’s assessment of the pleura, as well as a difficulty 
distinguishing benign pleural thickening from malignancy.16 Even if the CT scan looks very suspicious 
for malignancy, it can still be challenging to distinguish mesothelioma from pleural metastasis from 
the lung or other body systems (such as breast, ovarian or renal cancers).17 CT scanning is currently 
used as a method of monitoring disease following diagnosis e.g. response to chemotherapy, 
assessing progression, etc. However, similar problems remain and given that mesothelioma does not 
grow as a spherical mass but more as a pleural or peritoneal rind (Figure 1B), it can be challenging 
for radiologists to quantify any change in tumour bulk. Scoring systems that have been modified for 
mesothelioma’s unique morphology exist but have their limitations.18 
 
Figure 1; Imaging modalities in mesothelioma. A- Chest radiograph showing large right sided pleural 
effusion, B- Coronal CT image showing significant right sided pleural thickening and nodularity, C- 
Chest radiograph showing left sided pleural thickening and lung volume loss, D- Horizontal PET 
image showing right sided pleural enhancement posteriorly.  
 
 
Magnetic resonance imaging (MRI) is developing as a method of diagnosing and staging 
mesothelioma. Using diffusion-weighted imaging, recent studies have shown the accuracy of MRI is 
high for differentiating benign from malignant pleural disease.19 In addition, it may be possible to 
differentiate between different subtypes of mesothelioma at initial assessment.20 PET-CT imaging is 
a rapidly developing area in the diagnosis and staging of mesothelioma. It relies on 
contemporaneously acquired CT imaging and assessment of uptake of fluourine 18-
flurodeoxyglucose (FDG) into tissues. Uptake of FDG is usually higher in more metabolically active 
malignant tissue so will be more vivid on imaging (Figure 1D).21 The advantage of PET-CT over 
standard CT or MRI is the ability to detect local and distant spread of disease so it can be more 
accurately staged, so is often utilised in potential surgical patients.22 Its disadvantages include false 
positives in cases of pleural infection, inflammation and prior pleurodesis and limited availability 
outside of specialist centres.23 
 
Histocytological investigations 
For any patient who attends pleural/respiratory clinic with symptoms or signs suspicious for pleural 
mesothelioma their diagnostic pathway will depend on the presence or absence of pleural fluid on 
radiological imaging. Often the first line diagnostic procedure will be a diagnostic or therapeutic 
aspiration of pleural fluid (known as a thoracocentesis). Typically this fluid is sent to the 
biochemistry, microbiology and cytology laboratory and information regarding protein and glucose 
content, culture results and predominant cell types returned. The yield of malignant cells seen on 
pleural fluid cytology is notoriously low for mesothelioma  (10-20%). 24 Consequently, the majority of 
patients will go on to have further invasive diagnostic investigations in order to obtain a tissue 
biopsy either via USS guided pleural biopsy, direct visualisation using thoracoscopy, or an open 
surgical VATS (video-assisted thoracoscopic surgery) procedure. This improves the diagnostic yield to 
over 90%.25  
 Immunohistochemistry 
Even once a tissue sample is obtained a diagnosis of mesothelioma can be challenging because of 
the tumour’s wide range of morphological appearances. Additionally, the pleura and peritoneum are 
common sites for metastases from other malignancies. Differentiating mesothelioma from 
adenocarcinoma (from metastases of lung or breast cancer) in a tissue biopsy poses particular 
difficulties. For this reason basing the diagnosis purely on microscopic appearance is not 
recommended and various immunohistochemical methods are employed by pathologists. Although 
exact methodology varies hugely between centres,  guidelines generally advocate a combination of 
at least two positive mesothelial (Calretinin, Cytokeratin 5/6, Wilms Tumour 1, D-240) and at least 
two negative adenocarcinoma immunohistochemical markers (TTF1, CEA, Ber-EP4) for a positive 
diagnosis of mesothelioma. The pathologist should also be aware of the clinical and radiological 
context.  
 
Treatment of mesothelioma 
Given the invasive nature of mesothelioma, for the majority of patients, treatment has a palliative 
intent from diagnosis. Systemic therapies for mesothelioma have changed little in the last decade. A 
landmark study in 2003 found that a combination of the anti-folate Pemetrexed to platinum based 
therapy (cisplatin or carboplatin) improved survival in a non-placebo RCT.26 This led to the 
standardisation of first line chemotherapy across the UK although there is considerable variation in 
the numbers of patients offered chemotherapy nationally. 27 Despite being the only NICE approved 
treatment, this combination only adds an average of 2 months to overall survival with a response 
rate of around 30% 28 and significant side effect burden.29 The role of maintenance or second-line 
chemotherapy is uncertain. Maintenance pemetrexed is safe but its efficacy is yet to be 
established.30 Several second-line agents have been assessed, with positive results using vinorelbine, 
gemcitabine or re-challenging with pemetrexed but no national guidance exists on the topic 
currently. 31-34 
In the future biological therapy will play a greater role following results from the MAPS trial which 
demonstrated that the addition of bevacizumab to standard chemotherapy had a survival benefit of 
2 months compared to chemotherapy and placebo.35 This anti-VEGF monoclonal antibody is not yet 
approved by NICE but given this, and a number of other promising biological studies, the treatment 
for mesothelioma is likely to become more complex, with increasing cost implications and emphasis 
on early identification of treatment response. 
Radiotherapy for mesothelioma is employed as a palliative measure to improve symptoms, such as 
chest wall invasion or procedure tract metastases, or as an adjunct to chemotherapy and surgery. 
Surgery for mesothelioma is a highly controversial topic. Several centres in the UK will offer radical 
surgery to patients with early stage disease and good performance status, and case series often 
report excellent survival. However, these series are usually based on highly selected patients with 
sparse randomised data. Several surgical techniques exist as do the neo-adjuvant therapies that 
accompany them. The MARS trial (2011) was one the first randomised trial of surgery for 
mesothelioma and compared extra-pleural pneumonectomy (EPP) (where all macroscopically visible 
tumour is removed in a large open operation) to no surgery. 36 Although there has been considerable 
disagreement in the interpretation of the data, the trial concluded that EPP should not be offered to 
patients and might actually be harmful. Another more recent RCT of a less invasive surgical 
technique (video-assisted thoracoscopic partial pleurectomy or VAT-PP) also demonstrated no 
improvement in survival or quality of life in the surgical arm.37 There may be a role for pleurectomy 
decortication in some patients with mesothelioma and this the subject of a current trial in the UK 
(MARS2), the results of which are awaited with interest.  
 
Potential role of biomarkers: Diagnosis 
Using biomarkers to diagnose mesothelioma is an attractive concept for a number of reasons. Firstly, 
there is a clear 'at-risk' population in those who have been previously exposed to asbestos. Secondly, 
the presenting symptoms and radiological findings are difficult to distinguish from other benign and 
malignant pleural diseases. Thirdly, even with a high index of suspicion, current methods of 
histocytological diagnosis are invasive and may be inappropriate in a proportion of patients. 
Fourthly, once tissue is obtained the tumour can still be difficult to distinguish from other 
malignancies. Consequentially a large body of research has investigated the ability of serum and 
pleural fluid biomarkers to diagnose mesothelioma both individually and in panels. 
 
Potential role of biomarkers: Prognosis or treatment monitoring 
As discussed above, for the majority of patients, treatment for mesothelioma has a palliative intent. 
Any intervention therefore must careful balance improved life expectancy with quality of life. The 
standard of care with pemetrexed and cisplatin has a response rate of around 30% with a significant 
side effect profile and limited impact on symptoms. Oncologists are understandably very interested 
in selecting out patients who are likely to respond to chemotherapy at baseline or early in 
treatment. Additionally, in the few centres that offer surgery there is considerable pre-operative 
assessment to ensure that only patients who are most likely to benefit are put forward for surgery. 
However, there are very few radiological markers at baseline that can predict prognosis. 
In patients who receive chemotherapy oncologists will usually perform a CT scan mid cycle to assess 
response. As discussed above, because mesothelioma grows as a pleural rind as opposed to 
spherically like many other cancers it is difficult to monitor using conventional CT scanning. A 
biomarker that could measure response to chemotherapy or predict recurrence would be of huge 
benefit to oncologists. 
 Mesothelin 
Soluble Mesothelin (SM) is a 40kDa cell membrane bound glycoprotein overexpressed by the 
epithelioid component of malignant mesothelial cells. It is attached to the cell surface by 
phosphatidylinositol and although its role is uncertain it likely facilitates cell-adhesion and possibly in 
cell-to-cell recognition and signalling (see Figure 2). It was initially identified in the serum samples of 
patients with ovarian cancer before being found in high levels in the serum, plasma, pleural fluid and 
urine of patients with mesothelioma.38 The first clinical study of SM, published in 2003, showed that 
serum concentrations were significantly higher in patients with mesothelioma compared to healthy 
controls, asbestos exposed patients or those with other inflammatory or malignant lung 
conditions.39 They also demonstrated that serum SM levels are higher in epithelioid compared to 
non-epithelioid tumours and are positively correlated with tumour bulk. This paper reported a 
sensitivity of 84% (95% CI 73–93) for diagnosing mesothelioma from other pleural diseases with a 
specificity of 100% (91–100), although numbers were small (44 patients with mesothelioma). This 
finding led to a large number of subsequent and larger studies of serum SM as a diagnostic and/or 
screening biomarker. In 2014, Cui et al performed a meta-analysis of all studies that had examined 
the diagnostic ability of serum and pleural fluid SM. 40 There was considerable heterogeneity 
between studies in terms of patient characteristics (most notably within the control groups), ELISA 
kits and cut-offs used, as well as evidence of publication bias. The majority of studies used the 
commercial MesomarkTM ELISA, with 4 using other platforms. The cut-offs used to define an 
abnormal result ranged from 0.5nmol/L to 3.3nmol/L with most studies using a 'data specific' level 
as opposed to a pre-defined clinically convenient level. From the 28 studies of serum SM included in 
the analysis the pooled summary estimates of sensitivity and specificity were 0.61 and 0.87 
respectively. For a malignancy which is otherwise difficult to diagnose and has huge implications for 
the individual, an inability to exclude mesothelioma with a negative result limits its clinical utility. 
Given that a positive result increases the likelihood of having mesothelioma six-fold there may be a 
place for serum SM in patients who are unsuitable for or decline more invasive diagnostic 
procedures if the pre-test probability is high. For example, an elderly patient with a significant 
history of asbestos exposure presenting with a unilateral effusion. The results presented for pleural 
fluid mesothelin levels were superior to serum with pooled estimates of sensitivity and specificity of 
0.79 and 0.85 respectively but large variation in cut-offs used (3.5 to 24.05 nmol/L). 
 
Figure 2; Schematics showing maturation of mesothelin protein. Precursor protein for mesothelin is 
synthesized as a 622-amino acid polypeptide with a calculated molecular mass of 77 kDa. The potential signal 
peptide (SP) and the glycosylphosphatidyl inositol anchor signal sequence (GASS) are predicted at the NH2 
terminus and the COOH terminus, respectively. The precursor protein has four predicted glycosylation sites 
(CHO) and a furin cleavage site (RR). Cleavage at the furin site generates membrane-bound mesothelin (green) 
and the secretory protein megakaryocyte-potentiating factor (red). Reprinted from Clinical Cancer Research , 
2004, Volume 10, 3937–3942 , Hassan, Mesothelin: A New Target for Immunotherapy, with permission from 
AACR. 
 
Additional work has been done on a potential role of serum SM in screening at risk populations 
(asbestos exposed workers and their families). In principle mesothelioma is an attractive screening 
target with a well-defined at risk population of asbestos exposed individuals. A number of studies 
showed promising results when looking retrospectively 41 at SM's ability to selecting out early stage 
disease or those at risk of developing mesothelioma but with a false positive rate of 90% in some 
prospective studies (Creaney 2015 Present Status and Future Directions- book reference) it's 
accuracy falls below that of an acceptable screening test. 
Another area where serum mesothelin has shown promise (beyond an adjunct to diagnosis) is in the 
monitoring of mesothelioma during treatment. Mesothelin is positively correlated with both tumour 
stage and radiological bulk. Several surgical case series have shown that levels fall dramatically post 
debunking surgery. A literature review revealed 9 studies that assessed the utility of serial 
mesothelin measurements (see Table 1). Although heterogeneous in terms of primary outcome and 
study population, all found that a falling mesothelin from baseline correlated with treatment 
response or improved overall survival. Despite being approved by the FDA for treatment monitoring, 
oncologists continue to rely on radiological markers of response. This is because many patients 
(especially with sarcomatoid histology) will have low or undetectable mesothelin levels despite 
advanced disease. Also uncertainty exists around the appropriate sampling intervals, clinically 
significant cut offs for monitoring and how to handle results in patients with renal dysfunction 
(which causes false elevation in SM levels). 42 However, given the emergence of immune therapies 
for mesothelioma which further invalidate current radiological markers due to infiltration of tumour 
by immune cells, which appears as ‘pseudo-progression', and recent evidence that PET-CT adds little 
to treatment monitoring, 43 a large prospective study is required to evaluate the true role of 
mesothelin in this area. 
  
Table 1- Nine studies assessing the role of serum mesothelin to monitor mesothelioma.  
Author  
,year 
Treatment  
(no. of patients) 
Threshold for 
SM change 
Summary of results 
Bonotti, 
2016 44 
Chemotherapy- 56 20% Overall change in SM levels from baseline closely correlated with clinical response 
(p<0.001). 
Hooper, 
2015 43 
 
Chemo- 58, 
BSC- 15 
0% Within the chemotherapy group a falling serum SM was associated with longer time 
to progression (p<0.001), and improved OS (p=0.031).  
Hassan,  
2014 45 
 
Chemo & Im- 20 15% Fall in serum SM correlated with radiological response on CT with 70% accuracy 
(p=0.003).  
Nowak, 
2013 46 
 
Bio- 53 0% Median change in serum SM correlated with sum change in tumour bulk on FDG-PET 
(p<0.05). % change in serum SM was associated with TTP (p<0.001) but not OS.  
Franko, 
2012 47 
 
Chemo- 64, 
BSC- 4, Surgery- 10  
n/a Significantly lower mean serum SM in partial response or stable disease compared to 
progressive disease (p=0.001).  
Hollevoet, 
2011 48  
Chemo- 57, 
Surgery- 5 
15% Partial response to chemotherapy correlated with a 34% fall in SM (p=0.010) 
compared to a 54% rise in progressive disease (p<0.001).  
Creaney, 
2011 49 
 
Chemo- 61, BSC- 25, 
Surgery – 8 
25% Correlation between change in serum SM and CT (p=0.023) and FDG-PET markers 
(p<0.001) Also, a falling SM was associated with better OS (19 months) compared to 
static (13 months) or rising levels (15 months). (p=0.001). 
Wheatley-
Price, 2010 50  
Chemo- 21, BSC- 13, 
Surgery -8 
10% or 
5nmol/L 
Relative change in serum SM from baseline significantly associated with disease 
progression (p<0.010). 
 
Grigoriu,  
2009 51 
 
Chemo- 20, Im- 16, 
BSC- 4 
10% OS higher in patients with stable SM compared to increasing (p=0.012). Rising SM 
levels correlated with progressive disease in 12/16 patients (had high SM levels at 
baseline).  
Chemo- chemotherapy, Bio- biological therapy, Im- immunotherapy, BSC- best supportive care, Surg- surgery, Mod RECIST CT- Modified Response 
Evaluation Criteria In Solid Tumors CT, OS- overall survival, TTP- time to progression. 
 
 
Megakaryocyte Potentiating Factor (MPF) 
MPF, also called N-ERC/mesothelin as it is formed from the same precursor protein as SM, is a more 
novel biomarker. It has similar expression to SM given that it is also originates from epithelioid 
mesothelioma cells (see Figure x). With respect to diagnosis there is little additional benefit to SM 
with similar downfalls due to low levels in non-epithelioid disease. In terms of disease monitoring 
some studies report slightly improved accuracy but given only marginal improvement the focus of 
future research in this area will likely be focused on SM.45, 48 
 
Osteopontin 
Osteopontin (OPN) is a glycoprotein that mediates cell to cell interactions and is over expressed in 
many tumours including breast, lung and colon malignancies.52 Studies have shown that it lacks the 
sensitivity to be used as a solely diagnostic test. A meta-analysis of serum and plasma OPN carried 
out in 2014 found a pooled sensitivity and specificity of 0.57 (95%CI: 0.52-0.61) and 0.81, 95%CI: 
0.79-0.84) respectively with considerable heterogeneity between the 9 studies.53 A thrombin 
cleavage site impedes reproducible measurements in serum for osteopontin so more recent 
literature has advocated plasma sampling to improve accuracy.54 In addition there appears to be 
little merit in serial monitoring of OPN. A study by Hollevoet et al showed that, unlike SM and MPF, 
osteopontin levels did not fall following surgery and did not correlate with treatment response from 
chemotherapy.48 Despite this, a potential role for osteopontin as a baseline predictor of poor 
prognosis has been demonstrated. Several studies have shown that a high baseline plasma 
osteopontin infers poor prognosis, exclusive of histology, treatment modality or indeed other 
biomarkers.48, 55 Further work is required to ascertain its utility outside of clinical trials, and given the 
variability in levels depending on ELISA used,56 it is important that any future research adopts a 
consensus approach. 
 
Fibulin-3 
Published in the New England Journal of Medicine the first major study of fibulin-3 in serum 
reported a sensitivity of 100% for detecting early stage mesothelioma from an asbestos exposed 
population with a specificity of 94.1%.57 These estimates would be high enough for inclusion into the 
routine diagnostic pathway. Unfortunately, several follow up studies using the same commercial 
ELISA assay were unable to replicate these results with a variety of estimates for sensitivity.58 A 
recent meta-analysis of 8 studies on the topic gave pooled estimates of sensitivity and specificity of 
0.87 (95% CI, 0.58 - 0.97) and 0.89 (95% CI, 0.77 - 0.95), respectively.59 Fibulin-3 is another 
glycoprotein that was initially discovered in high levels in another malignancy, namely glioma. It is 
thought to phosphorylate epidermal growth factor and thereby promote tumour growth and 
invasion.60 It is particularly overexpressed in pleural fluid from mesothelioma but estimates of 
sensitivity remain too low to maintain acceptable specificity. Several studies have shown that higher 
pleural fluid levels at baseline infer a poor prognosis but it is unclear whether this is primarily due to 
higher levels being found in more aggressive tumour types or if it offers additional prognostic 
information. 
 
Hyaluronic acid 
Hyaluronic acid (HA) is one of the earliest studied biomarkers in mesothelioma, found in both blood 
and pleural fluid, although serum analysis is less useful due to rapid (2.5 to 5min half-life) clearance 
from the systemic circulation by stablilin-2.61 HA is more stable in pleural fluid in the form of a large 
fibroblast formed polysaccharide. As a stand-alone test it is not particularly specific for 
mesothelioma and, given difficulties with its original testing methodology, it has had limited 
attention since the early 80/90s studies. More recently a combination of a more easily reproducible 
assay and combining results with other biomarkers has re-ignited interest in the pleural fluid analysis 
of HA. In 2013, Creaney et al demonstrated that when combined with pleural fluid SM the area 
under the curve for both biomarkers improved to 0.92 (C.I 0.86 to 0.96).62 Interestingly, the same 
study followed up the 96 patients with mesothelioma and found that pleural fluid HA was 
biphasically distributed within the cohort. When dichotomised at 75mg/L those with high effusion 
HA had much better survival (18.0m) compared to patients with low levels (12.6m) (p<0.01). This 
confirmed the finding of a previous study 63 and although several explanations have been postulated 
the exact pathophysiology is uncertain. Further work is required before the clinical utility of this 
finding can be fully assessed. 
 
Vascular Endothelial Growth Factor (VEGF) 
Pan-VEGF and its various isoforms have been the focus of enumerate studies of malignant and non-
malignant diseases of the lung. VEGF almost certainly has a role in pathophysiology of mesothelioma 
although it’s exact role probably varies depending on the specific isoform.64 Yasumitsu and 
colleagues compared levels of pan-VEGF in the serum and pleural effusion of 51 patients with 
mesothelioma to an asbestos exposed population.65 They found that levels were significantly higher 
in mesothelioma, with highest levels in epithelioid disease but without the accuracy to be included 
in a diagnostic pathway (sensitivity was 70.6%, and the specificity was 88.1%). Notably, VEGF level 
was correlated with stage of disease and worse survival, which probably relates to its well-
documented effects on tumour angiogenesis. It is of particular importance in mesothelioma given 
the emergence of antiangiogenic VEGF-targeted treatments (Bevacizumab) that have been shown to 
improve survival when given in combination with pemetrexed and cisplatin.35 No studies have 
demonstrated any ability of serum VEGF to select responders from non-responders for biologic 
therapy, but this area demands further study given the development of promising but expensive 
biologicals.46, 66 
 
Future biomarkers and biomarker panels 
Ongoing research into biomarkers is directed at the validation of existing biomarkers or panels of 
existing biomarkers, and discovery of novel biomarkers. As mentioned above the combination of 
mesothelin and hyaluronic acid improved the overall diagnostic accuracy of both. Another study 
combined two molecular classes of biomarker by analysing plasma mesothelin values with the 
microRNA miR-103a-3p.67 This improved the sensitivity and specificity of mesothelin alone from 74% 
and 89% to 95% and 81% respectively. 
More novel approaches involve the protenomic discovery of previously unidentified biomarkers in 
serum and pleural fluid and their validation in a second cohort. Such a study was performed by 
Ostroff et al who demonstrated promising results using a 13 protein panel, 68 reporting area under 
the curve (AUC) results of 0.98±0.04 in blinded verification cohort and 0.95±0.04 in a validation 
cohort (38 patients with mesothelioma). This proteomic assay is currently being validated in a multi-
centre prospective trial alongside fibulin-3, it is of note that none of the 13 classifier proteins have 
previously been associated with mesothelioma.69 Many studies exist using this technique of protein 
discovery but the importance of external validation is paramount. Another study from Morré and 
colleagues focused on the presence of two mesothelioma specific ENOX2 protein transcript variants 
in the serum of 17 patients pre and post diagnosis of mesothelioma.70 When compared to patients 
who had been exposed to asbestos but without a diagnosis of mesothelioma, one or both proteins 
were detectable up to 10 years prior to diagnosis and with a mean of 6.2 years prior to the onset of 
clinical symptoms. This finding requires further prospective investigation but if useful could be used 
to detect mesothelioma at an early and more treatable stage. 
 
Conclusion 
The role of biomarkers in mesothelioma has been assessed at almost every stage of the disease 
process including screening, diagnosis, prognostication and monitoring. Despite being an attractive 
target for screening or diagnosis no single biomarker has sufficient reproducibility in differentiating 
mesothelioma from other more common benign or malignant conditions. Promising results are 
being seen using biomarker panels but none have been external validated in prospective trials. 
 Mesothelioma is a difficult disease to prognosticate/ monitor both clinically and radiologically 
representing another potential role for biomarkers. Results from several studies have supported the 
use of serum mesothelin as a method of monitoring disease during treatment although questions 
remain around its utility in non-epithelioid disease. High levels of plasma osteopontin at baseline 
appears to be an independent poor prognostic indicator although further studies are required to 
assess the clinical usefulness of this finding. Given that treatments for mesothelioma are now 
developing following years of inertia the pressure to select responders early is growing. With the 
proliferation of biomarker discovery projects and formalised tissue storage for mesothelioma 
samples (i.e. MesoBank) it is essential that promising biomarkers are investigated beyond the initial 
detection stage. 
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